30 Sept 2026, 08:52
Company UpdateMS
COVCLEO DIAGNOSTICS LTD
Announcement history available from 1 August 2025
Fromto
24 Sept 2026, 09:09
Company UpdateMS
17 Sept 2026, 10:18
Meetings & Governance—
17 Sept 2026, 10:14
Meetings & Governance—
10 Sept 2026, 17:01
Meetings & Governance—
10 Sept 2026, 09:14
Company UpdateMS
3 Sept 2026, 08:55
Company UpdateMS
24 Aug 2026, 16:33
Director Interests—
24 Aug 2026, 16:16
Securities Administration—
24 Aug 2026, 16:14
Securities Administration—
24 Aug 2026, 16:12
Securities Administration—
21 Aug 2026, 16:22
Director Interests—
20 Aug 2026, 16:01
Company Administration—
20 Aug 2026, 15:52
Financial ResultsMS
29 July 2026, 09:39
Quarterly ReportsMS
13 July 2026, 09:10
Company UpdateMS
7 July 2026, 16:41
Director Interests—
28 May 2026, 16:18
Securities Administration—
28 May 2026, 16:12
Securities Administration—
20 May 2026, 09:25
Company UpdateMS
29 Apr 2026, 09:32
Quarterly ReportsMS
28 Apr 2026, 08:26
Company UpdateMS
31 Mar 2026, 09:04
Company UpdateMS
23 Mar 2026, 08:29
Company UpdateMS
25 Feb 2026, 16:24
Financial ResultsMS
18 Feb 2026, 09:44
Company UpdateMS
29 Jan 2026, 08:24
Quarterly ReportsMS
5 Jan 2026, 15:26
Substantial Holders—
29 Dec 2025, 11:23
Letters & Addresses—
29 Dec 2025, 11:16
Securities Administration—
29 Dec 2025, 11:11
Securities Administration—
29 Dec 2025, 11:06
Securities Administration—
29 Dec 2025, 11:04
Securities Administration—
18 Dec 2025, 09:54
Securities Administration—
18 Dec 2025, 09:53
Capital RaisingMS
17 Dec 2025, 08:50
Trading Halt / SuspensionMS
28 Nov 2025, 16:31
Securities Administration—
26 Nov 2025, 08:25
Periodic ReportsMS
24 Nov 2025, 14:40
Meetings & Governance—
19 Nov 2025, 10:02
Company AdministrationMS
6 Nov 2025, 09:19
Company UpdateMS
31 Oct 2025, 14:39
Quarterly ReportsMS
30 Oct 2025, 09:44
Company UpdateMS
25 Sept 2025, 16:28
Meetings & Governance—
25 Sept 2025, 16:14
Meetings & Governance—
19 Sept 2025, 16:33
Securities Administration—
15 Sept 2025, 09:30
Company UpdateMS
5 Sept 2025, 16:34
Meetings & Governance—
26 Aug 2025, 16:55
Company Administration—
26 Aug 2025, 16:48
Financial ResultsMS
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 30 Sept 2026, 08:52 | Cleo Files Patents for its Ovarian Cancer Screening Test | Company Update | MS | 11001 | |
| 24 Sept 2026, 09:09 | CLEO Commences Ovarian Cancer Screening Test Development | Company Update | MS | 11001 | |
| 17 Sept 2026, 10:18 | Letter to Shareholders | Meetings & Governance | — | 08006, 16002 | |
| 17 Sept 2026, 10:14 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 10 Sept 2026, 17:01 | Notice Required Under ASX Listing Rule 3.13.1 | Meetings & Governance | — | 08006 | |
| 10 Sept 2026, 09:14 | CLIA Certified Lab selected - Pivotal US Clinical Validation | Company Update | MS | 11001 | |
| 3 Sept 2026, 08:55 | CLEO Receives First Batch of Commercial Test Kits | Company Update | MS | 11001 | |
| 24 Aug 2026, 16:33 | Change of Director's Interest Notice x 4 | Director Interests | — | 02009 | |
| 24 Aug 2026, 16:16 | Cleansing Notice | Securities Administration | — | 06018 | |
| 24 Aug 2026, 16:14 | Application for quotation of securities - COV | Securities Administration | — | 06020 | |
| 24 Aug 2026, 16:12 | Notification of cessation of securities - COV | Securities Administration | — | 06027 | |
| 21 Aug 2026, 16:22 | Change in Director's Interest Notice | Director Interests | — | 02009 | |
| 20 Aug 2026, 16:01 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 20 Aug 2026, 15:52 | Appendix 4E and 2026 Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 29 July 2026, 09:39 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19004, 19009 | |
| 13 July 2026, 09:10 | CLEO Enters Analytical Validation Phase | Company Update | MS | 11001 | |
| 7 July 2026, 16:41 | Change in Director's Interest Notice | Director Interests | — | 02009 | |
| 28 May 2026, 16:18 | Cleansing Notice | Securities Administration | — | 06018 | |
| 28 May 2026, 16:12 | Application for quotation of securities - COV | Securities Administration | — | 06020 | |
| 20 May 2026, 09:25 | CLEO Establishes U.S. Reimbursement Pathway | Company Update | MS | 11001 | |
| 29 Apr 2026, 09:32 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19003, 19008 | |
| 28 Apr 2026, 08:26 | CLEO Commences Kit Manufacturing Ahead of FDA Submission | Company Update | MS | 11001 | |
| 31 Mar 2026, 09:04 | Sample Collection Completion for Pivotal US Clinical Trial | Company Update | MS | 11001 | |
| 23 Mar 2026, 08:29 | CLEO Optimises Biomarker Panel Ahead of FDA Submission | Company Update | MS | 11001 | |
| 25 Feb 2026, 16:24 | Appendix 4D and Half Yearly Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 18 Feb 2026, 09:44 | CLEO Confirms Next-Gen Platform for Ovarian Cancer Test | Company Update | MS | 11001 | |
| 29 Jan 2026, 08:24 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19002, 19007 | |
| 5 Jan 2026, 15:26 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 29 Dec 2025, 11:23 | Chairman's End of Year Letter to Shareholders | Letters & Addresses | — | 16002 | |
| 29 Dec 2025, 11:16 | Cleansing Notice | Securities Administration | — | 06018 | |
| 29 Dec 2025, 11:11 | Notification regarding unquoted securities - COV | Securities Administration | — | 06021 | |
| 29 Dec 2025, 11:06 | Application for quotation of securities - COV | Securities Administration | — | 06020 | |
| 29 Dec 2025, 11:04 | Application for quotation of securities - COV | Securities Administration | — | 06020 | |
| 18 Dec 2025, 09:54 | Proposed issue of securities - COV | Securities Administration | — | 06013 | |
| 18 Dec 2025, 09:53 | CLEO Raises $5m to Support U.S. Market Launch | Capital Raising | MS | 06003, 09014 | |
| 17 Dec 2025, 08:50 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 28 Nov 2025, 16:31 | Notice under Listing Rule 3.10A | Securities Administration | — | 06009 | |
| 26 Nov 2025, 08:25 | Cleo Strengthens Cash Position with $1.7m R&D Tax Refund | Periodic Reports | MS | 03014 | |
| 24 Nov 2025, 14:40 | Results of Annual General Meeting | Meetings & Governance | — | 08003 | |
| 19 Nov 2025, 10:02 | CLEO Appoints First Key Opinion Leader to Support US Market | Company Administration | MS | 12008 | |
| 6 Nov 2025, 09:19 | CLEO Significantly Expands Addressable Market | Company Update | MS | 11001 | |
| 31 Oct 2025, 14:39 | Quarterly activities and cashflow report | Quarterly Reports | MS | 19001, 19006 | |
| 30 Oct 2025, 09:44 | CLEO Successfully Completes Stage 1 MDSAP Audit | Company Update | MS | 11001 | |
| 25 Sept 2025, 16:28 | Letter to Shareholders | Meetings & Governance | — | 08001, 16002 | |
| 25 Sept 2025, 16:14 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 19 Sept 2025, 16:33 | Application for quotation of securities - COV | Securities Administration | — | 06020 | |
| 15 Sept 2025, 09:30 | Cleo Receives Positive FDA Feedback | Company Update | MS | 11001 | |
| 5 Sept 2025, 16:34 | Notice Required Under ASX Listing Rule 3.13.1 | Meetings & Governance | — | 08006, 12008 | |
| 26 Aug 2025, 16:55 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 26 Aug 2025, 16:48 | Appendix 4E and 2025 Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 |
1–50 of 52
1 / 2